Felodipine or hydrochlorothiazide/triamterene for treatment of hypertension in the elderly: Effects on blood pressure, hypertensive heart disease, metabolic and hormonal parameters

Blood Pressure

Volumn 5, Issue 3, 1996, Pages 154-163

  Trenkwalder, Peter ^a,b   Plaschke, Michael ^a   Aulehner, Richard ^a   Lydtin, Helmut ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b Starnberg Hospital   (Germany)

Author keywords

ambulatory blood pressure monitoring; diuretics; felodipine; hypertension in the elderly; hypertensive heart disease; myocardial ischemia

Indexed keywords

FELODIPINE; HYDROCHLOROTHIAZIDE; TRIAMTERENE;

AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029927126     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.3109/08037059609062124     Document Type: Article

References (58)

1. Amery A, Birkenhäger W, Brixko P, Bulpitt C, Clement D, Deruyterre M et al. Mortality and morbidity results from the European Working Party on high blood pressure in the elderly trial. Lancet 1985; i: 1349-54.
2. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338; 1281-5.
3. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 255: 3255-64.
4. Editorial. New trials in older hypertensives. Lancet 1991; 338; 1299-300.
5. Guidelines Sub-Committee. 1993 Guidelines for the management of mild hypertension: memorandum from the World Health Organization/International Society of Hypertension meeting. J Hypertens 1993; 11: 905-18.
6. Deutsche Liga zur Bekämpfung des hohen Blutdruckes e.V. Empfehlungen zur Hochdruckbehandlung in der Praxis und zur Behandlung hypertensiver Notfälle. 11th ed. Heidelberg 1994.
7. Trenkwalder P, Ruland D, Stender M, et al. Prevalence, awareness, treatment and control of hypertension in a population over the age of 65: results from the Starnberg Study on Epidemiology of Parkinsonism and Hypertension in the Elderly (STEPHY). J Hypertens 1994; 12: 709-16.
8. Saltiel E, Ellrodt AG, Monk JP, Langley MS. Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs 1988; 36: 387-428.
9. Todd PA, Faulds D. Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disease. Drugs 1992; 44: 251-77.
10. Hosie J, Mulder AW, Westberg B. Felodipine once daily in elderly hypertensives. J Hum Hypertens 1991; 5: 49-53.
11. Trenkwalder P, Dobrindt R, Plaschke M, Lydtin H. Usefulness of simultaneous ambulatory electrocardiographic and blood pressure monitoring in detecting myocardial ischemia in patients >70 years of age with systemic hypertension. Am J Cardiol 1993; 72: 927-31.
12. O'Brien E, Mee F, Atkins N, O'Malley K. Accuracy of the SpaceLabs 90207 determined by the British Hypertension Society Protocol. J Hypertens 1991; 9: 573-4.
13. Staessen J, Fagard R, Lijinen P, Thijs L, van Hoof R, Amery A. Ambulatory blood pressure monitoring in clinical trials. J Hypertens 1991; 9 (Suppl 1): 13-9.
14. Trenkwalder P, Dobrindt R, Aulehner R, Lydtin H. Antihypertensive treatment with felodipine but not with a diuretic reduces episodes of myocardial ischemia in elderly patients with hypertension. Eur Heart J 1994; 15: 1673-80.
15. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man: Anatomic Validation of the method. Circulation 1977; 55: 613-8.
16. Sealey JE. Plasma renin activity and plasma prorenin assays. Clin Chem 1991; 37: 1811-9.
17. Arendt RM, Lampen UW, Heucke L, Schmoeckel M, Sühler K, Richter WO. Increased endothelin plasma concentrations in patients with coronary artery disease or hyperlipoproteinemia without coronary events. Res Exp Med 1993; 193: 225-30.
18. Materson BJ, Reda DJ, Cushman WC et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328: 914-21.
19. Ménard J. Critical assessment of combination therapy development. Blood Pressure 1993; 2 (Suppl 1): 5-9.
20. Perry HM. Update on multicenter clinical trials in hypertension. Curr Opinion Cardiol 1993; 8: 780-5.
21. Vetter W. Individualisierte Hochdrucktherapie. Muench Med Wschr 1992; 134: 781.
22. Fariello R, Boni E, Corda L et al. Extended release felodipine in essential hypertension. Variations in blood pressure during whole-day continuous ambulatory recording. Am J Hypertens 1991; 4: 27-33.
23. O'Brien E, Sheridan J, O'Malley K. Dippers and non-dippers. Lancet 1988; ii: 397.
24. Ekelund LG, Ekelund C, Rössner S. Antihypertensive effects at rest and during exercise of a calcium blocker, nifedipine, alone and in combination with metoprolol. Acta Med Scand 1982; 212: 71-5.
25. Lorimer A, McAlpine H, Rae A et al. Effects of felodipine on rest and exercise heart rate and blood pressure in hypertensive patients. Drugs 1985; 29 (Suppl 2): 154-7.
26. Franz IW. Wirkung antihypertensiver Pharmaka auf den Blutdruck Hochdruckkranker während dynamischer und isometrischer Belastung. In: Franz IW, ed. Belastungsblutdruck bei Hochdruckkranken. Berlin Heidelberg New York: Springer, 1993: 187-220.
27. Greven J, Heidenreich O. Diuretic drugs in hypertension. In: van Zwieten PA, ed. Handbook of Hypertension, vol 3: Pharmacology of antihypertensive drugs. Amsterdam: Elsevier, 1984: 66-101.
28. van Zwieten PA. Comparative mechanisms of action of diuretic drugs in hypertension. Eur Heart J 1992; 13 (Suppl G): 2-4.
29. Singh BN, Gecht HS, Nademanee K, Chew CYC. Electrophysiologic and hemodynamic effects of slow channel blocking drugs. Prog Cariovasc Drugs 1982; 15: 103-32.
30. Kaplan NM. Clinical hypertension. Baltimore: Williams & Willkins, 1990.
31. Joint National Committee. The Fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993; 153: 154-83.
32. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987; 82: 421-6.
33. Lydtin H, Trenkwalder P. Calcium antagonists. A critical review. Berlin Heidelberg New York: Springer, 1990.
34. Messerli FH. Antihypertensive therapy - going to the heart of the matter. Circulation 1990; 81: 1128-35.
35. Massie BM. Effect of diuretic therapy on hypertensive left ventricular hypertrophy. Eur Heart J 1992; 13 (Suppl G): 53-60.
36. Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by electrocardiogram: Prevalence, incidence, and mortality in the Framingham Study. Ann Intern Med 1969; 71: 89-101.
37. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Left ventricular mass as a risk factor for incidence of coronary heart disease in an elderly cohort: The Framingham Study. Ann Intern Med 1989; 110: 101-7.
38. Wetzchewald D, Klaus D, Garanin G, Lohr E, Hoffmann J. Regression of left ventricular hypertrophy during long-term antihypertensive treatment - a comparison between felodipine and the combination of felodipine and metoprolol. J Intern Med 1992; 231: 303-8.
39. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.
40. Psaty BM, Heckbert SR, Koepsell TD et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620-5.
41. Multiple Risk Factor Intervention Trial Research Group (MRFIT). Coronary heart disease death, nonfatal acute myocardial infarction and other clinical outcomes in the multiple risk factor intervention trial. Am J Cardiol 1986; 58: 1-13.
42. Siscovick DS, Raghunathan TE, Psaty BM et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994; 330: 1852-7.
43. Trost BN, Weidmann P. Effects of calcium antagonists on glucose hemostasis and serum lipids in non-diabetic and diabetic subjects: a review. J Hypertens 1987; 5 (Suppl 4): 81-104.
44. Schoen RE, Frishman WH, Shamoon H. Hormonal and metabolic effects of calcium channel antagonists in man. Am J Med 1988; 84: 492-504.
45. Nilsson-Ehle P, Swedish MC Study Group. Felodipine does not affect plasma lipoprotein concentrations. J Cardiovasc Pharmacol 1990; 15 (Suppl 4): S112 (abstract).
46. Scherstén BFE, Swedisch MC Study Group. Unchanged lipid and lipotrotein conentrations in hypertensive patients with type II diabetes mellitus during one year of treatment with felodipine and nifedipine compared to placebo. Am J Hypertens 1994; 7: 73A (abstract).
47. Ferrari P, Rosman J, Weidmann P. Antihypertensive agents, serum lipoproteins and glucose metabolism. Am J Cardiol 1991; 67: 26B-35.
48. Weidmann P, de Courten M, Ferrari P. Effects of diuretics on the plasma lipid profile. Eur Heart J 1992; 13 (Suppl G): 61-7.
49. Kohvakka A, Salo H, Gordin A. Antihypertensive and biochemical effects of different doses of hydrochlorothiazide alone or in combination with triamterene. Acta Med Scand 1986; 219: 381-6.
50. Prichard BNC, Owens CWI, Woolfs CWI. Adverse reactions to diuretics. Eur Heart J 1992; 13 (Suppl G): 96-103.
51. Hulthén UL, Katzman PL. Renal effects of acute and long-term treatment with felodipine in essential hypertension. J Hypertens 1988; 6: 231-7.
52. Van Brummelen P, Schalekamp MADH. Body fluid volumes and the response of renin and aldosterone to short- and long-term thiazide therapy of hypertension. Acta Med Scand 1980; 207: 259-64.
53. Toffelmire EB, Slater K, Corvol P, Menard J, Schambelan M. Response of plasma prorenin and active renin to chronic and acute alterations of renin secretion in normal humans. J Clin Invest 1989; 75: 679-87.
54. Doig JK, Lees KR, Reid JL. The effect of drugs on the renin-angiotensin system in man. In: Robertson JIS, Nicholls MG, eds. The renin-angiotensin system. London, New York: Gower Medical Publishing, 1991: 80.1-80.19.
55. Kohno M, Yasunari K, Murakawa KI et al. Plasma immunoreactive endothelin in essential hypertension. Am J Med 1990; 88: 614-9.
56. Lüscher TF, Oemar BS, Boulanger CM, Hahn AWA. Molecular and cellular biology of endothelin and its receptors - Part II. J Hypertens 1993; 11: 121-6.
57. Kiowski W, Lüscher TF, Linder L, Bühler FR. Endothelin-1-induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation 1991; 83: 469-75.
58. Liu JJ, Casley D, Wojta J et al. Effects of calcium- and ETA-receptor antagonists on endothelin-induced vasoconstriction and levels of endothelin in the human internal mammary artery. Clin Exp Pharmacol Physiol 1994; 21: 49-57.